BioNTech and Pfizer: Covid-19 vaccine study boosts imagination on the stock exchange

BioNTech and Pfizer are far from alone in working on a vaccine against the pathogen of the Covid-19 pandemic, the SARS-CoV-2 virus, which has been raging for months. But today the Mainz-based company and its US partner own the stage on the stock exchange. The reason: The biotech company and the pharmaceutical giant have presented good first interim study data from the current US arm of the clinical test series with the vaccine candidate BNT162b1. Even with lower doses, this has provided an immune response that the two companies are highly satisfied with. The news for the shares of the two companies was that the vaccine candidate did not experience any problematic developments regarding the tolerance data, and that BioNTech boss Ugur Sahin said that it was well tolerated in a telephone conference.

In a first reaction, BioNTech’s share price on NASDAQ rose to $ 79.38 after an initial trading halt (the rush to paper was high) after yesterday’s $ 66.74 biotech stock went off and on in the run-up to today’s news was clearly revitalized and recorded price gains – the stock exchange had bet exactly on today’s news. In the meantime, however, the first euphoria has calmed down, after a slide to $ 67.35 in the meantime, the share price is now back at $ 70.82 and is gaining 6.11 percent in value. The BioNTech share was able to clearly confirm the latest chart buying signals despite today’s profit taking. Important chart-technical hurdles were overcome at $ 60.43 and $ 64.45, among others – we had that early on technical opportunities of BioNtech shares pointed out, well ahead of these massive price breaks, which are now clearly bullish in the chart-technical image of the biotech title.

Related Articles

Back to top button